Part of the Controlled Access, this Vaccination Confirmation Form verifies that iptacopan can only be dispensed once Novartis receives written confirmation that each patient has received vaccination against N. meningitidis and S. pneumoniae infections and/or receipt of prophylactic antibiotic treatment (in accordance with national guidelines).

This material has been developed and funded by Novartis Pharmaceuticals UK Ltd and is intended only for UK patients with paroxysmal nocturnal haemoglobinuria (PNH) who have been prescribed iptacopan.

This brochure aims to provide guidance and mitigate possible risk of infections during iptacopan treatment, and haemolysis after discontinuation.

This material has been developed and funded by Novartis Pharmaceuticals UK Ltd and is intended only for UK patients with paroxysmal nocturnal haemoglobinuria (PNH) who have been prescribed iptacopan and their caregivers. This guide aims to provide you with important safety information for iptacopan.